C-reactive protein: pathogenetic characteristics and possible therapeutic target

It is known that the key mediator of acute phase response and marker of inflammation is C-reactive protein (CRP), the study of the role of which in the development of not only cardiovascular, but also infectious diseases has acquired particular relevance at the present time. CRP can be involved in a...

Full description

Bibliographic Details
Main Authors: E. A. Utkina, O. I. Afanasyeva, S. N. Pokrovsky
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2021-07-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/4138
id doaj-bf6f789f33b14941b0eba0b808df9401
record_format Article
spelling doaj-bf6f789f33b14941b0eba0b808df94012021-07-28T14:02:41Zrus«FIRMA «SILICEA» LLC Российский кардиологический журнал1560-40712618-76202021-07-0126610.15829/1560-4071-2021-41383140C-reactive protein: pathogenetic characteristics and possible therapeutic targetE. A. Utkina0O. I. Afanasyeva1S. N. Pokrovsky2National Medical Research Center of CardiologyNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyIt is known that the key mediator of acute phase response and marker of inflammation is C-reactive protein (CRP), the study of the role of which in the development of not only cardiovascular, but also infectious diseases has acquired particular relevance at the present time. CRP can be involved in all stages of the atherosclerotic process, including activation of the complement system and vascular endothelial cells, thrombosis, lipid accumulation, and apoptosis.The review describes modern concepts of the structure, biological and pathophysiological properties of CRP, its value as a cardiovascular risk predictor, as well as existing methods for reducing its blood level.According to recent studies, cardiovascular patients who achieved lower CRP levels with drug therapy had better clinical prognosis, making CRP an attractive therapeutic target. Currently, a search is underway for approaches to correct CRP levels associated with both the development of novel drugs and therapeutic apheresis methods to remove CRP from blood plasma.https://russjcardiol.elpub.ru/jour/article/view/4138atherosclerosisinflammationc-reactive protein
collection DOAJ
language Russian
format Article
sources DOAJ
author E. A. Utkina
O. I. Afanasyeva
S. N. Pokrovsky
spellingShingle E. A. Utkina
O. I. Afanasyeva
S. N. Pokrovsky
C-reactive protein: pathogenetic characteristics and possible therapeutic target
Российский кардиологический журнал
atherosclerosis
inflammation
c-reactive protein
author_facet E. A. Utkina
O. I. Afanasyeva
S. N. Pokrovsky
author_sort E. A. Utkina
title C-reactive protein: pathogenetic characteristics and possible therapeutic target
title_short C-reactive protein: pathogenetic characteristics and possible therapeutic target
title_full C-reactive protein: pathogenetic characteristics and possible therapeutic target
title_fullStr C-reactive protein: pathogenetic characteristics and possible therapeutic target
title_full_unstemmed C-reactive protein: pathogenetic characteristics and possible therapeutic target
title_sort c-reactive protein: pathogenetic characteristics and possible therapeutic target
publisher «FIRMA «SILICEA» LLC 
series Российский кардиологический журнал
issn 1560-4071
2618-7620
publishDate 2021-07-01
description It is known that the key mediator of acute phase response and marker of inflammation is C-reactive protein (CRP), the study of the role of which in the development of not only cardiovascular, but also infectious diseases has acquired particular relevance at the present time. CRP can be involved in all stages of the atherosclerotic process, including activation of the complement system and vascular endothelial cells, thrombosis, lipid accumulation, and apoptosis.The review describes modern concepts of the structure, biological and pathophysiological properties of CRP, its value as a cardiovascular risk predictor, as well as existing methods for reducing its blood level.According to recent studies, cardiovascular patients who achieved lower CRP levels with drug therapy had better clinical prognosis, making CRP an attractive therapeutic target. Currently, a search is underway for approaches to correct CRP levels associated with both the development of novel drugs and therapeutic apheresis methods to remove CRP from blood plasma.
topic atherosclerosis
inflammation
c-reactive protein
url https://russjcardiol.elpub.ru/jour/article/view/4138
work_keys_str_mv AT eautkina creactiveproteinpathogeneticcharacteristicsandpossibletherapeutictarget
AT oiafanasyeva creactiveproteinpathogeneticcharacteristicsandpossibletherapeutictarget
AT snpokrovsky creactiveproteinpathogeneticcharacteristicsandpossibletherapeutictarget
_version_ 1721268831858458624